Onconetix, Inc. (NASDAQ:ONCO) Short Interest Up 252.7% in March

Onconetix, Inc. (NASDAQ:ONCO) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 738,300 shares, a growth of 252.7% from the February 28th total of 209,300 shares. Based on an average daily trading volume, of 9,570,000 shares, the short-interest ratio is presently 0.1 days. Approximately 7.9% of the company’s shares are short sold.

Hedge Funds Weigh In On Onconetix

Several hedge funds have recently bought and sold shares of the business. Millennium Management LLC purchased a new stake in shares of Onconetix during the fourth quarter valued at $25,000. Geode Capital Management LLC purchased a new position in Onconetix in the 4th quarter worth about $35,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Onconetix by 83.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 562,691 shares of the company’s stock valued at $2,926,000 after buying an additional 256,612 shares in the last quarter. Institutional investors own 23.89% of the company’s stock.

Onconetix Trading Down 14.9 %

Shares of ONCO traded down $0.02 during mid-day trading on Friday, reaching $0.09. 7,997,680 shares of the company’s stock traded hands, compared to its average volume of 3,173,100. Onconetix has a 12 month low of $0.08 and a 12 month high of $21.40. The stock’s 50-day moving average is $0.38 and its two-hundred day moving average is $1.75.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.